Welcome to our dedicated page for Biohaven Ltd. news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven Ltd. stock.
Biohaven Ltd. (NYSE: BHVN) is a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of transformative treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Leveraging multiple proprietary drug development platforms, Biohaven is advancing an impressive product pipeline that addresses a variety of diseases, ranging from neuromuscular and metabolic disorders to antibody-drug conjugates for cancer and obsessive-compulsive disorder.
Biohaven's notable product candidates include:
- Glutamate Modulation: Troriluzole, currently in Phase 3 trials for obsessive-compulsive disorder, offers hope for patients with inadequate responses to standard treatments.
- Myostatin Inhibition: Taldefgrobep alfa, in Phase 3 studies for spinal muscular atrophy and being evaluated for obesity treatment, targets muscle growth regulation pathways.
- Ion Channels: BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, is in clinical development for epilepsy and mood disorders.
- Inflammation & Immunology: BHV-1300 and BHV-1310, from the innovative extracellular protein degradation platform, aim to treat autoimmune diseases by lowering IgG levels.
- Oncology: BHV-1510, a Trophoblast Cell Surface Antigen-2 (Trop-2) directed ADC, shows promise in treating select advanced epithelial tumors.
Recent milestones highlighted at the 42nd Annual J.P. Morgan Healthcare Conference and other events include significant progress in these areas and the initiation of pivotal human studies. CEO Dr. Vlad Coric emphasized the company's strong focus on neuroscience, immunology, and oncology, with near-term potential in these fields.
Financial updates reveal solid funding for future advancements, supported by a public offering that raised $230 million. Biohaven's robust clinical and preclinical pipelines are backed by an experienced leadership team and a strong financial foundation, underlining the company's capacity for rapid, efficient drug development.
The company’s leadership in neuroscience was underscored at the 2024 American Academy of Neurology Annual Meeting, featuring multiple presentations on Kv7 ion channel modulation, MoDEs, TRPM3 antagonism, and TYK2/JAK1 inhibition. Looking ahead, Biohaven is poised for a groundbreaking year, with multiple INDs planned and significant clinical data expected across its portfolio.
For more information, visit Biohaven's website.
Biohaven Pharmaceutical (BHVN) has announced a new investigator-led clinical trial for a CGRP-receptor antagonist aimed at treating plaque psoriasis, led by Dr. Richard Granstein from Weill Cornell Medicine. This study will measure disease severity and quality of life after 16 weeks of treatment compared to placebo. The trial highlights Biohaven's commitment to exploring CGRP's role in dermatological conditions, enhancing their neuroinnovation portfolio, which includes FDA-approved Nurtec for migraines. The trial's commencement signifies potential expansion into dermatological therapies.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced its partnership with the National Ataxia Foundation (NAF) on November 11, 2020, becoming the first industry member to support the NAF Drug Development Collaborative. This initiative aims to enhance the development of treatments for Ataxia, a group of neurodegenerative diseases without current FDA-approved therapies. Biohaven is actively enrolling participants in a Phase 3 clinical trial for its drug, troriluzole, targeting Spinocerebellar Ataxia.
Biohaven Pharmaceutical Holding Company (NYSE: BHVN) reported third-quarter 2020 financial results, highlighting net revenues of $17.7 million for NURTEC ODT, significantly surpassing expectations amid pandemic challenges. The drug has garnered over 220,000 prescriptions in just six months, indicating strong market uptake. The company anticipates NURTEC's annual US market potential to reach $4B to $5B. Recent milestones include FDA acceptance of an sNDA for NURTEC's preventive use, and $60 million raised for BioShin to expand their clinical portfolio in the Asia-Pacific region.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will report its third quarter 2020 financial results on November 9, 2020, at 8:30 a.m. ET. The earnings call will cover results for the quarter ending September 30, 2020, alongside recent accomplishments and future milestones. Participants can join via telephone or the company's website. Biohaven specializes in innovative therapies for neurological and neuropsychiatric diseases, including the FDA-approved NURTEC™ ODT for migraine treatment, with a pipeline targeting various crucial disorders.
Biohaven Pharmaceutical Holding Company (NYSE: BHVN) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for migraine prevention. The PDUFA goal date for the FDA's review is set for 2Q2021. NURTEC ODT, launched in March 2020, is the first orally disintegrating tablet approved for acute migraine treatment and potentially addresses both acute and preventive needs. Clinical trials indicate a significant reduction in monthly migraine days for patients using rimegepant. The drug is expected to offer a convenient alternative to injectable therapies.
Biohaven Pharmaceutical (NYSE: BHVN) announced a successful $60M Series A funding for its Asia-Pacific subsidiary, BioShin Limited. The investment, led by OrbiMed, aims to advance Biohaven's clinical portfolio, including the upcoming Phase 3 study of NURTEC™ ODT for migraine treatment in China and Korea. BioShin also plans to enroll sites for a global trial of troriluzole in Spinocerebellar Ataxia. The funding allows BioShin to operate independently without relying on Biohaven's financial support. Biohaven retains majority ownership of BioShin.
Biohaven Pharmaceutical (BHVN) announced FDA authorization to initiate clinical trials for oral zavegepant (BHV-3500) and achieved first-in-human dosing in a Phase 1 trial. The company secured up to $250 million in funding to advance its CGRP receptor antagonist program, which includes both intranasal and oral formulations for migraine and non-migraine indications. Intranasal zavegepant showed superior efficacy over placebo in earlier trials for migraine treatment. This advances Biohaven's portfolio aimed at neurological disorders.
Biohaven Pharmaceutical (NYSE: BHVN) reported a net loss of $180.9 million for Q2 2020, equating to $3.08 per share, a slight improvement from the previous year's loss of $211.1 million. The company achieved net product revenues of $9.7 million from NURTEC ODT, showing strong prescription growth driven by effective virtual engagement strategies during the COVID-19 pandemic. Biohaven secured a $500 million non-dilutive credit facility and announced a $450 million funding agreement with Royalty Pharma to support its pipeline developments while maintaining a robust cash position of $263.9 million.
Biohaven Pharmaceutical (NYSE: BHVN) has secured a $500 million non-dilutive term loan from Sixth Street to support the commercialization of NURTEC ODT and for general corporate purposes. The terms allow for $375 million to be accessed immediately, with an additional $125 million contingent on achieving $45 million in net sales of NURTEC ODT in early 2021. CEO Vlad Coric emphasized the confidence in their growth following the launch of NURTEC ODT, while Sixth Street noted the shifting landscape of CGRP-targeting migraine therapies.
Biohaven Pharmaceutical (NYSE: BHVN) will report its second quarter 2020 financial results on August 10, 2020, at 8:00 a.m. ET. The earnings call will review the company's recent accomplishments and anticipated milestones, including its innovative therapies targeting neurological and neuropsychiatric diseases. Biohaven is known for its FDA-approved treatment, NURTEC™ ODT, for migraines and has a broad pipeline focused on various conditions. Interested parties can access the call via phone or through the company's website.
FAQ
What is the current stock price of Biohaven Ltd. (BHVN)?
What is the market cap of Biohaven Ltd. (BHVN)?
What does Biohaven Ltd. specialize in?
What are some of Biohaven's key product candidates?
What recent milestones has Biohaven achieved?
How is Biohaven funded for its future projects?
What is Biohaven's approach to treating autoimmune diseases?
Where can I find more information about Biohaven's clinical trials?
Who leads Biohaven Ltd.?
What are the primary therapeutic areas Biohaven is focusing on in 2024?
What recent events highlight Biohaven's advancements in neuroscience?
How does Biohaven plan to use the funds from its recent offering?
